stockrow
Friday 6 November 2026
Export PROF’s income statement to Excel — free account
Profound Medical
PROF Healthcare Medical Devices
Profound Medical’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, up 50.7% from fiscal 2024.
- Revenue
- +85.9%
- EPS
- +18.8%
- Free cash flow
- +47.9%
- Total debt
- +0.71%
Quarter to September 2026, against a year earlier
7.13
0.25
+3.63%
Follow PROF
Alert me
Profound Medical (PROF) P/E ratio
Profound Medical has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 27 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RXST RxSight, Inc. compare | n/m |
| CLPT ClearPoint Neuro, Inc. compare | n/m |
| QSI Quantum-Si Incorporated compare | n/m |
| TLSI TriSalus Life Sciences, Inc. compare | n/m |
| TMCI Treace Medical Concepts, Inc. compare | n/m |
| PROF Profound Medical | n/m |
| LAB Standard BioTools Inc. compare | 1.8× |
| ELMD Electromed, Inc. compare | 19.4× |
| INFU InfuSystems Holdings, Inc. compare | 32.0× |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)